Background

UPL Guides 18% EBITDA Surge and Targets $700 Million FY27 NPP Revenue

UPL projects a 14-18% surge in Q1 FY27 EBITDA and a target of $1 billion revenue for its NPP segment by FY31, supported by a $350 million CapEx plan.

Author Image
Sahi Markets
Published: 12 May 2026, 09:27 AM IST (1 day ago)
Last Updated: 12 May 2026, 09:27 AM IST (1 day ago)
2 min read
Reviewed by Arpit Seth

Market snapshot: UPL Limited has issued a robust growth guidance for FY27, signaling a strong recovery in the global agrochemical cycle. Following its Capital Markets Day, management projected double-digit growth in both top-line and bottom-line metrics for the first quarter, backed by strategic deleveraging and expansion into specialty chemicals.

Data Snapshot

  • Q1 FY27 Revenue Growth: 10% to 14% guided
  • Q1 FY27 EBITDA Growth: 14% to 18% guided
  • FY27 CapEx: $300M to $350M (vs $261M in FY26)
  • NPP Segment: $700M revenue target for FY27
  • Net Debt/EBITDA: Target range of 1.2x to 1.5x

What's Changed

  • CapEx intensity is increasing from $261M in FY26 to a peak of $350M in FY27 to fuel backward integration.
  • Working capital cycle is being normalized to ~65 days from the aggressive 57 days seen in FY26.
  • Strategic shift towards the NPP segment, aiming for a $1 billion revenue milestone by FY31 at a 12% CAGR.

Key Takeaways

  • Guidance suggests high-margin specialty chemicals will drive EBITDA expansion faster than revenue growth.
  • The company has successfully deleveraged, bringing Net Debt/EBITDA below 1.6x as of FY26.
  • Q1 remains seasonally slower, but double-digit growth targets indicate strong demand visibility.

SAHI Perspective

UPL's transition from a debt-heavy post-patent player to a specialty-led innovation giant is gaining traction. The $350 million CapEx commitment during a period of debt reduction confirms management's confidence in internal cash accruals and margin stability.

Market Implications

The positive guidance is likely to re-rate the agrochemical sector, shifting focus from destocking fears to volume-led recovery. Capital allocation toward backward integration will likely insulate margins against global price volatility in raw materials.

Trading Signals

Market Bias: Bullish

Guidance for 18% EBITDA growth and successful debt reduction to sub-1.6x levels support a positive outlook for the stock as it enters the FY27 cycle.

Overweight: Agrochemicals, Specialty Chemicals, Fertilizers

Underweight: Logistics (Cost Pressures), Post-Patent Commodities

Trigger Factors:

  • Monsoon progression in India and Brazil
  • Raw material price stability in China
  • Successful execution of the NPP $700M target

Time Horizon: Medium-term (3-12 months)

Industry Context

The global agrochemical industry is emerging from a two-year destocking phase. UPL's focus on bio-solutions (NPP) aligns with the global shift toward sustainable farming inputs, which command higher margins than traditional pesticides.

Key Risks to Watch

  • Elongation of working capital cycle beyond the 65-day target
  • Seasonal volatility in Latin American demand
  • Unfavorable currency fluctuations affecting debt servicing costs

Recent Developments

On May 11, 2026, UPL's board recommended a 300% dividend (₹6 per share) following FY26 results that beat guidance with 11% revenue growth. The company also repaid $500 million in debt in March 2026 to strengthen its balance sheet.

Closing Insight

UPL is prioritizing quality of earnings over sheer volume. By targeting high-margin segments like NPP and specialty chemicals, the company is effectively building a defense against the cyclicality of the core agrochemical business.

FAQs

Why is UPL expecting higher working capital days of 65 in FY27?

Management is normalizing the cycle to ~65 days from the exceptionally low 53-57 days in FY26 to support anticipated volume growth and ensure adequate inventory levels for peak seasons.

What is the significance of the $1 billion NPP target for investors?

This is a second-order signal of margin expansion; as the NPP (Natural Plant Protection) segment grows to $1B by FY31 at a 12% CAGR, UPL's overall EBITDA profile will shift away from lower-margin generics toward premium bio-solutions.

How does the 300% dividend impact retail shareholders?

The ₹6 per share dividend reflects strong cash flow generation despite the $350 million CapEx plan, rewarding long-term holders while maintaining a sustainable payout ratio.

High Performance Trading with SAHI.

All topics